FDA Approves Baxfendy, the First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension
AstraZeneca's baxdrostat (Baxfendy) became the first aldosterone synthase inhibitor approved in the US on May 18, 2026, giving the estimated 23 million Americans whose blood pressure remains uncontrolled on two or more drugs a new mechanistic option.